A recent study published in Diabetes, Obesity and Metabolism indicates that GLP-1 drugs, commonly used to treat type 2 diabetes and obesity, may also lower the risk of age-related macular degeneration (AMD). The research analyzed data from over 157,000 patients and found an 18%…
As the popularity of GLP-1 weight-loss drugs grows, body acceptance becomes increasingly challenging, particularly in a social media landscape filled with weight-loss marketing. E…
A recent study funded by the NIH has uncovered how newer oral GLP-1 drugs, including orforglipron and danuglipron, affect the brain's reward circuits in mice, potentially reducing…
A recent study has found that GLP-1 drugs like Wegovy and Ozempic, used for obesity and type 2 diabetes, may be associated with a higher risk of hair loss, particularly non-scarri…
A recent analysis reveals that while obesity drugs like GLP-1s can lead to significant weight loss, they often do not enhance quality of life or cardiovascular health for many pat…
A recent survey by ZipHealth explores the complexities of disclosing GLP-1 medication use, such as Ozempic, in dating scenarios. While many users reported positive dating experien…
Recent discussions surrounding GLP-1 drugs, particularly Ozempic, have raised questions about their potential role in cancer risk reduction. While some studies suggest a lower inc…
Research from the University of Hong Kong indicates that GLP-1 medications may help prevent lung scarring in individuals with type 2 diabetes following COVID-19. The study highlig…
The beauty industry is rapidly evolving in response to the adoption of GLP-1 weight-loss drugs, creating a new market for beauty products that promise to counteract the side effec…
In a stunning twist of regulatory fate, the FDA has issued new hair-raising guidelines for users of GLP-1 drugs like Ozempic and Mounjaro, warning of a 37-68% increased risk of ha…